2023年5月3日

更新从美国医疗保险和医疗补助服务中心(CMS)很快就会打开大门主要为虚拟以现实为基础的医疗报销。CMS最近创建了一个新的二级医疗通用程序编码系统为虚拟现实设备(HCPCS)代码,RelieVRx(及其附带的软件)。确定地方下的设备耐用医疗设备、假肢、矫形和物资(DMEPOS)类别中获益。这个更新是针对应用程序提交的AppliedVR Inc .)、数字医疗公司,专门从事虚拟疗法。AppliedVR的浸入式虚拟现实产品,RelieVRx FDA-authorized用于治疗慢性腰痛。它包括一个耳机,一个专利呼吸放大器和软件指导患者纳入研究支持疼痛管理技术通过日常会话。它必须通过零售销售规定,不可用。马修·Stoudt AppliedVR的联合创始人和首席执行官,评论更新4月份在一份事先准备好的声明中。“我们想象身临其境的疗法是一种未来的选择一生的药片或昂贵的手术。使广泛覆盖RelieVRx计划将提供一个强大的,然而数以百万计的人负担得起的和可伸缩的数字解决方案。“HCPCS代码E1905被描述为一个“虚拟现实设备认知行为治疗(cbt),包括预定的治疗软件。“它在4月1日生效。 Reimbursement rates have not yet been established, but CMS has requested pricing information from AppliedVR to be considered during future HCPCS public meetings in order to make a payment determination. Although the determination does not yet mandate coverage, it does suggest that CMS is open to considering how related technologies can improve patient care and potentially reduce costs. Vendors and clinicians have also taken note of the potential for VR-based treatments for behavioral health, as was evident in several booths at the annual HIMSS conference held in April. In line with these trends, the U.S. Food and Drug Administration recently indicated that there has been an increase in applications for approval of VR medical devices. They recently released a list of all 39 VR products that are currently legal to be marketed in the U.S. through 510(k) clearance, De Novo classification or premarket application approval. Highlighting the benefits of VR care, the FDA noted the technology's potential in the diagnostic and treatment process, citing its "ability to deliver both standard and entirely new types of content in highly immersive and realistic ways, remotely, and tailored to a variety of clinical contexts." More to come soon.